ScholarWorks@SUNGKYUNKWAN UNIVERSITY

The Lancet Respiratory Medicine

Journal Title

  • The Lancet Respiratory Medicine

ISSN

  • P 2213-2600 | 2213-2600

Publisher

  • Elsevier Limited
  • Elsevier

Listed on(Coverage)

JCR2014-2019
SJR2014-2019
CiteScore2014-2019
SCIE2014-2021
CC2016-2021
SCOPUS2017-2020
MEDLINE2016-2021
EMBASE2016-2020

Active

  • Active

    based on the information

    • SCOPUS:2020-10

Country

  • ENGLAND

Aime & Scopes

  • The Lancet Respiratory Medicine delivers comprehensive, clinically-focused coverage on all areas of respiratory medicine and critical care, including but not limited to: COPD, asthma, cystic fibrosis, IPF, pneumonia, influenza, tuberculosis, sarcoidosis, pulmonary hypertension, sleep medicine, respiratory infections, pulmonary vascular disease, lung cancer, tobacco control, thoracic and reconstructive surgery, mesothelioma, and palliative medicine. Continuing in The Lancet's tradition of publishing high-impact content that influences medical practice, each monthly issue of The Lancet Respiratory Medicine contains Original Research, Reviews, Personal Views, Comments, and News. The Lancet Respiratory Medicine is stringently edited and peer-reviewed to ensure the scientific merit and clinical relevance of its diverse content. Original Research is fast-tracked to publication within 8 weeks of submission (on average) and published Online First on www.thelancet.com before appearing in print. Now indexed in PubMed, Journal Citation Reports®, and Scopus, the journal accepts submissions of Original Research, Reviews, Personal Views, and Comments. Visit http://ees.elsevier.com/thelancetrm to learn more about our editorial scope and aims and to submit your manuscript. Gold or Green Open Access is available for research supported by selected funding agencies with whom Elsevier has an agreement. The journal is also freely available to readers in low-to-middle-income countries via the HINARI programme or via IP access at www.thelancet.com. To find out more about The Lancet Respiratory Medicine, visit www.thelancet.com/respiratory.

Homepage

Article List

1 - 9 out of 9 results.

SCIESCOPUS
Transfusion practice in patients receiving VV ECMO (PROTECMO): a prospective, multicentre, observational study

Martucci, G.[Martucci, Gennaro]; Schmidt, M.[Schmidt, Matthieu]; Agerstrand, C.[Agerstrand, Cara]; Tabatabai, A.[Tabatabai, Ali]; Tuzzolino, F.[Tuzzolino, Fabio]; Giani, M.[Giani, Marco]; Ramanan, R.[Ramanan, Raj]; Grasselli, G.[Grasselli, Giacomo]; Schellongowski, P.[Schellongowski, Peter]; Riera, J.[Riera, Jordi], et al.

ArticleIssue Date2023CitationThe Lancet Respiratory Medicine, v.11, no.3, pp.245 - 255PublisherElsevier Ltd
SCIESCOPUS
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial

Hoeper, MM[Hoeper, Marius M.]; Al-Hiti, H[Al-Hiti, Hikmet]; Benza, RL[Benza, Raymond L.]; Chang, SA[Chang, Sung-A]; Corris, PA[Corris, Paul A.]; Gibbs, JSR[Gibbs, J. Simon R.]; Grunig, E[Grunig, Ekkehard]; Jansa, P[Jansa, Pavel]; Klinger, JR[Klinger, James R.]; Langleben, D[Langleben, David], et al.

ArticleIssue Date2021CitationLANCET RESPIRATORY MEDICINE, v.9, no.6, pp.573 - 584PublisherELSEVIER SCI LTD
SCIESCOPUS
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Wu, Y.-L.[Wu, Y.-L.]; Cheng, Y.[Cheng, Y.]; Zhou, J.[Zhou, J.]; Lu, S.[Lu, S.]; Zhang, Y.[Zhang, Y.]; Zhao, J.[Zhao, J.]; Kim, D.-W.[Kim, D.-W.]; Soo, R.A.[Soo, R.A.]; Kim, S.-W.[Kim, S.-W.]; Pan, H.[Pan, H.], et al.

ArticleIssue Date2020CitationThe Lancet Respiratory Medicine, v.8, no.11, pp.1132 - 1143PublisherLancet Publishing Group
SCIESCOPUS
Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society

Hatabu, H[Hatabu, Hiroto]; Hunninghake, GM[Hunninghake, Gary M.]; Richeldi, L[Richeldi, Luca]; Brown, KK[Brown, Kevin K.]; Wells, AU[Wells, Athol U.]; Remy-Jardin, M[Remy-Jardin, Martine]; Verschakelen, J[Verschakelen, Johny]; Nicholson, AG[Nicholson, Andrew G.]; Beasley, MB[Beasley, Mary B.]; Christiani, DC[Christiani, David C.], et al.

ArticleIssue Date2020CitationLANCET RESPIRATORY MEDICINE, v.8, no.7, pp.726 - 737PublisherELSEVIER SCI LTD
SCIESCOPUS
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

Zhou, C.[Zhou, C.]; Kim, S.-W.[Kim, S.-W.]; Reungwetwattana, T.[Reungwetwattana, T.]; Zhou, J.[Zhou, J.]; Zhang, Y.[Zhang, Y.]; He, J.[He, J.]; Yang, J.-J.[Yang, J.-J.]; Cheng, Y.[Cheng, Y.]; Lee, S.-H.[Lee, S.-H.]; Bu, L.[Bu, L.], et al.

ArticleIssue Date2019CitationThe Lancet Respiratory Medicine, v.7, no.5, pp.437 - 446PublisherLancet Publishing Group
SCIESCOPUS
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

Leigh, NB[Leigh, Natasha B.]; Hellmann, MD[Hellmann, Matthew D.]; Hui, RN[Hui, Rina]; Carcereny, E[Carcereny, Enric]; Felip, E[Felip, Enriqueta]; Ahn, MJ[Ahn, Myung-Ju]; Eder, JP[Eder, Joseph Paul]; Balmanoukian, AS[Balmanoukian, Ani S.]; Aggarwal, C[Aggarwal, Charu]; Horn, L[Horn, Leora], et al.

ArticleIssue Date2019CitationLANCET RESPIRATORY MEDICINE, v.7, no.4, pp.347 - 357PublisherELSEVIER SCI LTD
SCIESCOPUS
Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis

Fregonese, F.[Fregonese, F.]; Ahuja, S.D.[Ahuja, S.D.]; Akkerman, O.W.[Akkerman, O.W.]; Arakaki-Sanchez, D.[Arakaki-Sanchez, D.]; Ayakaka, I.[Ayakaka, I.]; Baghaei, P.[Baghaei, P.]; Bang, D.[Bang, D.]; Bastos, M.[Bastos, M.]; Benedetti, A.[Benedetti, A.]; Bonnet, M.[Bonnet, M.], et al.

ArticleIssue Date2018CitationThe Lancet Respiratory Medicine, v.6, no.4, pp.265 - 275PublisherLancet Publishing Group
SCIESCOPUS
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study

Ahn, MJ[Ahn, Myung-Ju]; Kim, DW[Kim, Dong-Wan]; Cho, BC[Cho, Byoung Chul]; Kim, SW[Kim, Sang-We]; Lee, JS[Lee, Jong Seok]; Ahn, JS[Ahn, Jin-Seok]; Kim, TM[Kim, Tae Min]; Lin, CC[Lin, Chia-Chi]; Kim, HR[Kim, Hye Ryun]; John, T[John, Thomas], et al.

ArticleIssue Date2017CitationLANCET RESPIRATORY MEDICINE, v.5, no.11, pp.891 - 902PublisherELSEVIER SCI LTD
SCIESCOPUS
Two recent phase 2 trials of vandetanib in RET-rearranged NSCLC

Lee, SH[Lee, Se-Hoon]; Lee, JK[Lee, June-Koo]

ArticleIssue Date2017CitationLANCET RESPIRATORY MEDICINE, v.5, no.2, pp.E10 - E10PublisherELSEVIER SCI LTD
1
STATISTICS
Total View :5,372,769
Today View :3,359

RSS_1.0 RSS_2.0 ATOM_1.0

CONTACT US

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu

COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

BROWSE

한국어